ADMA Biologics, Inc.
Symbol: ADMA (NASDAQ)
Company Description:
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
- Today's Open: $14.7
- Today's High: $15.089
- Today's Low: $14.585
- Today's Volume: 992.19K
- Yesterday Close: $14.66
- Yesterday High: $14.92
- Yesterday Low: $14.445
- Yesterday Volume: 4.04M
- Last Min Volume: 389
- Last Min High: $15.038
- Last Min Low: $15.035
- Last Min VWAP: $15.03507
- Name: ADMA Biologics, Inc.
- Website: https://www.admabiologics.com
- Listed Date: 2013-10-17
- Location: RAMSEY, NJ
- Market Status: Active
- CIK Number: 0001368514
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $3.50B
- Round Lot: 100
- Outstanding Shares: 238.63M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-16 | 4 | View |
2025-08-15 | 4 | View |
2025-08-11 | SCHEDULE 13G | View |
2025-08-06 | 10-Q | View |
2025-08-06 | 8-K | View |
2025-08-01 | 4 | View |
2025-07-29 | SCHEDULE 13G/A | View |
2025-07-28 | 4 | View |
2025-07-28 | 4 | View |
2025-07-16 | 4 | View |
2025-07-15 | 144 | View |
2025-06-30 | 4 | View |
2025-06-18 | 4 | View |
2025-06-16 | 4 | View |
2025-06-12 | 144 | View |
2025-06-11 | 4 | View |
2025-06-10 | 4 | View |
2025-06-09 | 144 | View |
2025-06-04 | 8-K | View |
2025-06-04 | 144 | View |